GlassScriptPhysician profile
Jessica Maria Chan
NPI 1275927485
$8,888.44
in general payments reported to CMS, 2019-2025
45 companies · $2,234 in 2025
The $2,234 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.95 · 2021: $1,021 · 2022: $1,712 · 2023: $2,368 · 2024: $1,533 · 2025: $2,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,093 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,092.56 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,231.86 | 2020-2025 | Mounjaro, Trulicity, Lyumjev |
| Novo Nordisk INC | $1,075.35 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $723.11 | 2021-2025 | Freestyle Libre 3 |
| Insulet Corporation | $688.53 | 2021-2025 | Omnipod |
| Dexcom, INC. | $568.37 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $456.89 | 2021-2025 | Evenity, Prolia, Repatha |
| Corcept Therapeutics | $402.91 | 2021-2025 | Korlym |
| Radius Health, INC. | $397.61 | 2021-2025 | Tymlos |
| Abbvie INC. | $366.59 | 2022-2025 | Synthroid, Ubrelvy |
| Xeris Pharmaceuticals, INC. | $287.40 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.94 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $233.45 | 2021-2025 | Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $194.83 | 2022-2025 | |
| Medtronic, INC. | $184.98 | 2021-2024 | Intellis Adaptivestim, Minimed 780g |
| Kyowa Kirin, INC. | $147.23 | 2023-2025 | Crysvita |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $140.25 | 2022-2023 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $138.08 | 2023-2025 | |
| Tandem Diabetes Care, INC. | $136.06 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $130.03 | 2023-2025 | Isturisa, Signifor Lar |
| Novartis Pharmaceuticals Corporation | $128.46 | 2023-2025 | |
| Antares Pharma, INC. | $127.29 | 2021-2025 | Xyosted |
| Verity Pharmaceuticals INC. | $109.73 | 2024-2025 | Tlando |
| Mannkind Corporation | $78.25 | 2024-2025 | |
| Embecta Corp. | $69.00 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Exact Sciences Corporation | $60.32 | 2023-2025 | Cologuard Collection Kit |
| Alvogen INC | $56.28 | 2022-2024 | Teriparatide |
| Halozyme INC | $43.06 | 2023 | |
| Madrigal Pharmaceuticals | $39.35 | 2025 | Rezdiffra |
| Ascendis Pharma Endocrinology INC | $35.39 | 2023 | |
| Merck Sharp & Dohme LLC | $34.82 | 2021-2022 | |
| Abiomed | $31.72 | 2025 | |
| Horizon Therapeutics Plc | $31.24 | 2022-2023 | Tepezza |
| Pfizer INC. | $30.51 | 2021 | |
| Tolmar, INC. | $29.48 | 2023-2025 | Jatenzo |
| Rhythm Pharmaceuticals, INC. | $24.96 | 2025 | Imcivree |
| Sequel Med Tech, LLC | $20.34 | 2025 | Twiist |
| Ionis Pharmaceuticals, INC. | $19.95 | 2025 | Tryngolza |
| Edwards Lifesciences Corporation | $19.88 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Beta Bionics, INC. | $18.78 | 2023 | Ilet Bionic Pancreas |
| Averitas Pharma INC. | $18.28 | 2025 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $17.73 | 2021 | |
| Neurocrine Biosciences, INC. | $17.35 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $16.04 | 2021 | |
| Currax Pharmaceuticals LLC | $13.01 | 2023 | Nexletol, Contrave, Nexlizet |
| Esperion Therapeutics, INC. | $12.75 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.